Preparation method of solid dispersion medicine for treating hemorrhage

Abstract

The invention relates to a method for preparing a solid dispersion medicine for treating hemorrhagic disease. The solid dispersion medicine for treating the hemorrhagic disease is prepared according to the parts by weight as follows: 1-5 parts of dencichine, 0.4-2 parts of a cosolvent, 0.5-2.5 parts of a dispersion carrier and 0.1-0.5 part of a cryoprotectant. The invention also discloses a method for preparing the solid dispersion medicine and a method for preparing the solid dispersion medicine into various pharmaceutically acceptable dosage forms by adding pharmaceutic adjuvants, such as injection, oral solid preparation and preparations for external use. The solid dispersion medicine has obvious functions of preventing and treating hemorrhage. The medicine is prepared by a dispersion system and better disperses both in vivo and in vitro, which is beneficial to the absorption of human body, thus improving the haemostatic effect.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a preparation method of solid dispersion medicine for treating hemorrhage. Background technique [0002] Bleeding is one of the common emergencies involving various clinical departments in peacetime and wartime. Bleeding caused by trauma, surgery, or complications of certain diseases can cause reduced effective blood circulation, insufficient tissue perfusion, cellular hypoxia, metabolic disorders, and damage to important organ functions, resulting in shock or death. [0003] Because the causes of bleeding and the mechanism of coagulation and hemostasis are very complicated, the research on coagulation and hemostasis has always been one of the important topics for medical workers. [0004] Hemostatic methods and hemostatic drugs after hemorrhage are also the focus of clinical research. Common hemostatic means include surgical treatment and non-surgical treatment. ...

AI Technical Summary

Problems solved by technology

[0006] At present, many aspects of the research on hemostasis mechanism have entered the stage of molecular biochemistry, and based on the mechanism of coagulation and hemostasis, a large number of animal, plant and synthetic hemostatic agents have been developed, but they still cannot meet the clinical requirements in practical applications. A high-efficiency, low-toxic hemostatic agent, which can reduce the amount of bleeding and save the lives of patients in a timely manner, is still an urgent research and development target, with significant social benefits and broad market prospects

[0007] So far, a small amount of notoginseng has been reported as a hemostatic drug in the prior art of China. As introduced in the patent application with the publication number CN1292376A, a small amount of notoginseng can achieve the hemostatic effect, but at the same time it is pointed out that a slightly excessive amount of notoginseng It will produce neurotoxicity when used, and there is no better solution at present